CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.
Navneet MatharuSawitree RattanasophaSerena TamuraLenka MaliskovaYi WangAdelaide BernardAaron I HardinWalter L EckalbarChristian VaisseNadav AhituvPublished in: Science (New York, N.Y.) (2018)
A wide range of human diseases result from haploinsufficiency, where the function of one of the two gene copies is lost. Here, we targeted the remaining functional copy of a haploinsufficient gene using CRISPR-mediated activation (CRISPRa) in Sim1 and Mc4r heterozygous mouse models to rescue their obesity phenotype. Transgenic-based CRISPRa targeting of the Sim1 promoter or its distant hypothalamic enhancer up-regulated its expression from the endogenous functional allele in a tissue-specific manner, rescuing the obesity phenotype in Sim1 heterozygous mice. To evaluate the therapeutic potential of CRISPRa, we injected CRISPRa-recombinant adeno-associated virus into the hypothalamus, which led to reversal of the obesity phenotype in Sim1 and Mc4r haploinsufficient mice. Our results suggest that endogenous gene up-regulation could be a potential strategy to treat altered gene dosage diseases.
Keyphrases
- high fat diet induced
- genome wide
- insulin resistance
- metabolic syndrome
- transcription factor
- weight loss
- dna methylation
- type diabetes
- copy number
- weight gain
- genome wide identification
- crispr cas
- mouse model
- adipose tissue
- gene expression
- poor prognosis
- early onset
- binding protein
- endothelial cells
- body mass index
- skeletal muscle
- lymph node
- drug delivery
- cancer therapy
- cell free